Status: Recruiting
Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer
The purpose of the research is to determine the highest dose of an oral compound called zeaxanthin that can be safely taken each day in patients with advanced cancer, the toxicity profile of zeaxanthin, and the dose of zeaxanthin to use in future cancer clinical trials.
Participants needed: 72
Trial details
Phase: Phase 1Age: 18-99Biological sex: AllType: InterventionalSponsor: Valley Health SystemUpdated: Jun 5, 2026Locations: 1
Eligibility criteria
Stage IV or unresectable stage 3 histologically confirmed solid tumor malignancy... [+15]
Patients who have had chemotherapy or radiotherapy within 21 days prior to initi... [+35]